With PD-1 OK looming, Regeneron antes $100M on bluebird alliance for next-gen TCR cell therapy pact
Sometime in the next few months, we’re likely to see the FDA come through with an approval for the world’s 6th PD-1/L1 checkpoint inhibitor from Regeneron $REGN and its longtime development partners at Sanofi. But now the fast-growing Regeneron is also allying itself with bluebird bio $BLUE, putting up $100 million in equity cash on a 50/50 development deal aimed at creating a new pipeline of cell therapies with an eye to expanding the horizon in oncology with a new set of T cell receptor targets.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.